NCT02459002
- Conditions
- Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
- Locations
-
- University of Texas MD Anderson Cancer Center Houston, Texas, United States
Clinical trial condition
Non-small Cell Lung Cancer
Explore clinical trials studying Non-small Cell Lung Cancer. Study availability and eligibility vary by location and protocol.
1,335 public trials
330 recruiting studies
Non-small Cell Lung Cancer trial results
NCT01296113
- Conditions
- Blood-Borne Infections, Bronchial Neoplasms, Carcinoma, Bronchogenic, +24 more
- Locations
-
- Centre Hospitalier du Pays d'Aix Aix-en-Provence, France
- Annemasse - CH Ambilly, France
- Annecy - CH Annecy, France
- Avignon - CH Avignon, France
NCT03156868
- Conditions
- Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
- Locations
-
- Hospital de Elche Elche, Alicante, Spain
- Hospital de Torrevieja Torrevieja, Alicante, Spain
- ICO-Badalona Badalona, Barcelona, Spain
- Hospital General de Catalunya Sant Cugat del Vallès, Barcelona, Spain
NCT03150875
- Conditions
- Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
- Locations
-
- The First Affiliated Hospital Zhejiang University Hangzhou, Zhejiang, China
- Jiangsu Cancer Hospital Nanjing, China
NCT02803333
- Conditions
- Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
- Locations
-
- H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States
NCT02151604
- Conditions
- Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
- Locations
-
- Oxford University Hospitals NHS Trust Oxford, England, United Kingdom
Completed
mil60 Versus Bevacizumab in Patients With Treatment-naïve Non-squamous Non-small Cell Lung Cancer
NCT03196986
- Conditions
- Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
- Locations
-
- Cancer Institute/Hospital, Chinese Academy of Medical Sciences Beijing, China
- Peking University Shenzhen Hospital Shenzhen, China
Completed
Open-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain Metastases
NCT03463525
- Conditions
- Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
- Locations
-
- Research Site Stockholm, Sweden
NCT02713529
- Conditions
- Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +23 more
- Locations
-
- Research Site Atlanta, Georgia, United States
- Research Site Boston, Massachusetts, United States
- Research Site Boston, Massachusetts, United States
- Research Site Grand Rapids, Michigan, United States
Completed
A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation
NCT01859026
- Conditions
- Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
- Locations
-
- H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States